Contact Information

Currently Enrolling Trials

General Information

A launch has taken place in the U.S. of Amgen's consensus interferon (interferon alfacon-1, INFERGEN) for the treatment of chronic hepatitis C virus infection.

Approval Date: 1997-10-01

Company Name: Amgen

Back to Listings

13Jul
Decentralized Clinical Trials: Benefits of a Better Patient Experience

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here

INFERGEN (interferon alfacon-1)

Profile

Contact Information

Currently Enrolling Trials

General Information

Upcoming Events

Decentralized Clinical Trials: Benefits of a Better Patient Experience

Featured Products

Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

Stop Over-Reporting Adverse Events, FDA Officials Tell Sponsors

Ask the Experts: FDA Advice on Protocol Deviations

‘Snapback’ to Pre-Pandemic Trial Approaches Unlikely, Focus Is on Innovation

Despite Pandemic Positives, Crisis Highlights Issues with Growing Use of Service Providers

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.